Northfield Laboratories: Difference between revisions
Tom.Reding (talk | contribs) m +{{Authority control}} (2 IDs from Wikidata), WP:GenFixes on |
|||
| Line 70: | Line 70: | ||
It was founded in 1985 and has since been a mainly [[Research and Development]] company. Northfield's only product was PolyHeme, an oxygen-carrying [[blood substitute]], which failed to receive [[Food and Drug Administration]] (FDA) regulatory approval. On May 9, 2009, after being informed by the FDA the product's risks outweighed the benefits, the company shut down operations. During their operations, they incurred losses of about 220 million dollars.<ref>http://www.chicagotribune.com/business/chi-sat-northfield-0509-may09,0,1111961.story, retrieved May 9, 2009</ref> |
It was founded in 1985 and has since been a mainly [[Research and Development]] company. Northfield's only product was PolyHeme, an oxygen-carrying [[blood substitute]], which failed to receive [[Food and Drug Administration]] (FDA) regulatory approval. On May 9, 2009, after being informed by the FDA the product's risks outweighed the benefits, the company shut down operations. During their operations, they incurred losses of about 220 million dollars.<ref>http://www.chicagotribune.com/business/chi-sat-northfield-0509-may09,0,1111961.story, retrieved May 9, 2009</ref> |
||
The corporation was also criticized for some design elements of its clinical trials related to the need to perform critical care and resuscitation while patients were in grave clinical conditions due to the mechanisms of injury incurred and the consequent inability of patients to provide informed consent for treatment.<ref>http://blogs.abcnews.com/theblotter/2007/05/test_of_controv.html</ref> |
The corporation was also criticized for some design elements of its clinical trials related to the need to perform critical care and resuscitation while patients were in grave clinical conditions due to the mechanisms of injury incurred and the consequent inability of patients to provide informed consent for treatment.<ref>http://blogs.abcnews.com/theblotter/2007/05/test_of_controv.html</ref> |
||
==See also== |
==See also== |
||
* [[Clinical trial]] |
* [[Clinical trial]] |
||
| Line 76: | Line 77: | ||
==References== |
==References== |
||
{{Reflist}} |
|||
<references/> |
|||
==External links== |
==External links== |
||
* [http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=6914127&OS=6914127&RS=6914127 PolyHeme's patent.] |
* [http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=6914127&OS=6914127&RS=6914127 PolyHeme's patent.] |
||
{{Authority control}} |
|||
[[Category:Chemical companies of the United States]] |
[[Category:Chemical companies of the United States]] |
||
Revision as of 22:04, 5 April 2021
 | This article needs additional citations for verification. (November 2019) |
| Founded | 1985 |
|---|---|
| Defunct | May 9, 2009 |
| Headquarters | |
| Products | PolyHeme |
Northfield Laboratories Inc. ( former NASDAQ: NFLD ) was the maker of PolyHeme, a hemoglobin-based oxygen carrier (HBOC). The company was based in Evanston, Illinois, with Dr. Steven A. Gould as its Chief Executive Officer. As of May 31, 2005, the company had 68 employees.
It was founded in 1985 and has since been a mainly Research and Development company. Northfield's only product was PolyHeme, an oxygen-carrying blood substitute, which failed to receive Food and Drug Administration (FDA) regulatory approval. On May 9, 2009, after being informed by the FDA the product's risks outweighed the benefits, the company shut down operations. During their operations, they incurred losses of about 220 million dollars.[1] The corporation was also criticized for some design elements of its clinical trials related to the need to perform critical care and resuscitation while patients were in grave clinical conditions due to the mechanisms of injury incurred and the consequent inability of patients to provide informed consent for treatment.[2]
See also
References
External links
 | This chemical corporation-related article is a stub. You can help Wikipedia by expanding it. |
 | This United States corporation or company article is a stub. You can help Wikipedia by expanding it. |